STT3B-mediated N-glycosylation is essential for stabilization of EREG, combination of NGI-1 treatment with anti-PDLl therapy synergistically enhanced the efficacy of immunotherapy of HNSCC. This evidence concerns the gene STT3B and head and neck squamous cell carcinoma.